Published date: 22 November 2022

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 20 December 2022, 12pm

Contract summary

Industry

  • Health and social work services - 85000000

  • Health services - 85100000

Location of contract

Any region

Value of contract

£0

Procurement reference

20221122103809-68205

Published date

22 November 2022

Closing date

20 December 2022

Closing time

12pm

Contract start date

1 April 2023

Contract end date

31 March 2026

Contract type

Service contract

Procedure type

Not applicable

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No


Description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England Highly Specialised Services (referred to as the Commissioner), is undertaking a market engagement exercise to understand the current and future capacity and capability of providers and potential providers within this highly specialised area. All interested parties, including incumbent providers, are encouraged to register their interest and participate in the market engagement questionnaire which will provide feedback to commissioners. Please note that this is not a call for competition although the commissioner would encourage all potential providers to respond to this market engagement exercise. The outcome of this market engagement will help inform commissioners of the current and future capacity and capability of the market and will be considered to inform the commissioning approach.
This exercise is to commission a service that is able to expertly manage the provision of the Multiple Sclerosis Management Service for Children, including patients with suspected Multiple Sclerosis (MS) or equally rare 'MS-like', recurrent acquired demyelinating syndromes (ADS) or who have had a first demyelination episode and have a high risk of relapse which would require a similar treatment approach, including: Neuromyelitis Optica Spectrum Disorder (NMO, NMOSD) and other AQP4 antibody associated demyelination; Myelin Oligodendrocyte Glycoprotein (MOG) antibody associated relapsing demyelination and other forms of recurrent relapsing demyelination.
The MS Hub Lead Centres will be geographically spaced across the Regional areas of NHS England as follows:
i) Lot 1 - North comprising the NHS England Regions: the North East and Yorkshire; the North West,
ii) Lot 2 - the Midlands comprising the NHS England Regions: the Midlands; the East of England
iii) Lot 3 - London and the South: comprising the South East; the South West; London
The Commissioner reserves the right to direct award where competition is absent.

The questionnaire is available through the EU Supply portal: https://uk.eu-supply.com/login.asp?B=agcsu
The reference is 62208 and the closing date for submission of the completed questionnaire will be: 12pm, midday on Tuesday 20th December 2022.


About the buyer

Contact name

Josselin Canévet

Address

80 London Road
London
SE1 6LH
ENG

Email

josselin.canevet@nhs.net

Website

https://www.england.nhs.uk/